83. Un C., Zheng X., Tan Z. et al. Clinical Observation on Polyene Phosphatidyl Choline and Metformin in the Treatment of Type 2 Diabetes and Non-alcoholic Fatty Liver Disease // Clin Focus. — 2008. — Vol. 23, N 17. — P. 1272–3.
84. Yin Kong. Observation for curative effect of Essentiale in treatment of fatty liver caused by diabetes mellitus // Med J Qilu. — 2000. — Vol. 15. — P. 277–8.
85. Guo S. Observation on treatment of fatty liver disease with polyene phosphatidylcholine // China Foreign Med J. 2007. Vol. 5, Issue 10.
86. Kuntz E., Kuntz H.-D. Гепатология: учебное пособие и атлас. 3-е изд. — Springer Press, Heidelberg 2008; глава 40., С. 896.
87. Sas et al. Beneficial influence of polyunsaturated Phosphatidylcholine enhances functional liver condition and liver structure in patients with Nonalcoholic steatohepatitis Journal of Hepatology 2013; 58: S549 (EASL congress 2013) & Hepatol Int (2013) 7 (Suppl 1):S71.
88. Singal A.K., Jampana S.C., Weinman S.A. Liver Int. 2011; 31(10): 1432–1448.
89. OkiyamaW. et al. J Hepatol. 2009 Jun; 50(6): 1236–1246.
90. MazzellaN., Ricciardi L.M., Mazzotti A., Marchesini G. The role of medications for the management of patients with NAFLD. Clin Liver Dis. 2014 Feb;18(l):73–89. doi: 10.1016/j. cld.2013.09.005.
91. Hallsworth K., Avery L., Trenell M.I. Targeting Lifestyle Behavior Change in Adults with NAFLD During a 20-min Consultation: Summary of the Dietary and Exercise Literature. Curr Gastroenterol Rep. 2016 Mar;18(3):ll. doi: 10.1007/S11894-016-0485-1.
